Peer-Reviewed Publication
Oncoimmunology2021;10(1):2005280.January 1, 2021Journal Article
Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Jeong Hun Kim1,2,3, Won Suk Lee1,2, Hye Jin Lee1,2,3, Hannah Yang1,2, Seung Joon Lee1,3, So Jung Kong1,2, Soyeon Je4, Hyun-Jin Yang4, Jongsun Jung5, Jaekyung Cheon1,2,3, Beodeul Kang1,2,3, Hong Jae Chon1,2,3, Chan Kim1,2,3
1Laboratory of Translational Immuno-Oncology, Seongnam, Korea.
2Medical Oncology, Department of Internal Medicine,CHA Bundang Medical Center, Cha University, Seongnam, Korea.
3Graduate School of Department of Biomedical Science, Cha University, Seongnam, Korea.
4Medical Science Study Centre, Syntekabio Inc, Seoul, South Korea.
5Insilico Clinical Trial Research Center, Syntekabio Inc, Daejeon, South Korea.
Abstract
Kynurenine (Kyn) is a key inducer of an immunosuppressive tumor microenvironment (TME). Although indoleamine 2,3-dioxygenase (IDO)-selective inhibitors have been developed to suppress the Kyn pathway, the results were not satisfactory due to the presence of various opposing mechanisms. Here, we employed an orally administered novel Kyn pathway regulator to overcome the limitation of anti-tumor imm…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans